Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.
暂无分享,去创建一个
K. Döhner | R. Schlenk | H. Döhner | M. Heuser | F. Thol | A. Ganser | C. Schmoor | K. Götze | W. Brugger | M. Schittenhelm | C. Schwaenen | M. Lübbert | S. Scholl | J. Duyster | C. Müller-Tidow | U. Germing | H. Salih | R. Wäsch | A. Giagounidis | G. Heil | J. Krauter | A. Neubauer | B. Hackanson | H. Becker | M. de Wit | A. Kuendgen | E. Jost | G. Bug | A. May | H. Lindemann | M. Crysandt | Olga Grishina | O. Grishina
[1] A. Letai,et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.
[2] L. Bullinger,et al. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care , 2018, Leukemia.
[3] C. Delpierre,et al. Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey , 2018, Haematologica.
[4] Ø. Bruserud,et al. Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia – identification of responders by gene expression profiling of pretreatment leukemic cells , 2017, BMC Cancer.
[5] M. Konopleva,et al. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome , 2017, Haematologica.
[6] Nakul M. Shah,et al. DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats , 2017, Nature Genetics.
[7] S. Gore,et al. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings , 2017, Leukemia & lymphoma.
[8] M. Christmann,et al. Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells , 2016, Archives of Toxicology.
[9] K. Döhner,et al. All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study , 2016, Annals of Hematology.
[10] Wei Wu,et al. Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy , 2016, Annals of Hematology.
[11] M. Beckmann,et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses , 2016, Cell.
[12] H. Kantarjian,et al. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome , 2016, Leukemia.
[13] Trevor J Pugh,et al. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts , 2015, Cell.
[14] R. Greil,et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. , 2015, Blood.
[15] M. Wetzler,et al. Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia. , 2015, Clinical lymphoma, myeloma & leukemia.
[16] M. Scioli,et al. Vitamin A, Cancer Treatment and Prevention: The New Role of Cellular Retinol Binding Proteins , 2015, BioMed research international.
[17] J. Issa,et al. Results of phase 2 randomized study of low‐dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia , 2015, Cancer.
[18] T. Haferlach,et al. Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia , 2015, Haematologica.
[19] A. Ganser,et al. Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group , 2015, Annals of Hematology.
[20] M. Lübbert,et al. Epigenetic Priming of AML Blasts for All-trans Retinoic Acid-Induced Differentiation by the HDAC Class-I Selective Inhibitor Entinostat , 2013, PloS one.
[21] K. Döhner,et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy , 2012, Haematologica.
[22] S. Fröhling,et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. , 2012, Blood.
[23] H. Dombret,et al. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome , 2010, Oncotarget.
[24] Bob Löwenberg,et al. Review Articles (434 articles) , 2008 .
[25] C. Bradbury,et al. Elevated FOSB‐expression; a potential marker of valproate sensitivity in AML , 2009, British journal of haematology.
[26] S. Fröhling,et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B , 2009, Haematologica.
[27] M. Sorror,et al. Hematopoietic cell transplantation‐comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation , 2008, Cancer.
[28] Jorge Cortes,et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. , 2007, Blood.
[29] R. Hills,et al. A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.
[30] Michael Rytting,et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. , 2006, Blood.
[31] C. Steidl,et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all‐trans retinoic acid in patients with acute myeloid leukemia , 2006, Cancer.
[32] C. Schoch,et al. Clinical trial of valproic acid and all‐trans retinoic acid in patients with poor‐risk acute myeloid leukemia , 2005, Cancer.
[33] J. Herman,et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.